Pharmacokinetic approach in therapeutic monitoring of antineoplastic drugs and the impact on pharmacoeconomics: A systematic review.

Autor:	Barbosa IAB; Pharmacy Graduate Program, Federal University of Bahia, Salvador, BA, Brazil.; School of Pharmacy, Federal University of Bahia, Salvador, BA, Brazil., Silva TCD; Pharmacy Graduate Program, Federal University of Bahia, Salvador, BA, Brazil.; School of Pharmacy, Federal University of Bahia, Salvador, BA, Brazil., Souza MVP; School of Pharmacy, Federal University of Bahia, Salvador, BA, Brazil., Pedreira LA; School of Pharmacy, Federal University of Bahia, Salvador, BA, Brazil., Godoy ALPC; Pharmacy Graduate Program, Federal University of Bahia, Salvador, BA, Brazil.; School of Pharmacy, Federal University of Bahia, Salvador, BA, Brazil.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Jul; Vol. 29 (5), pp. 1218-1226. Date of Electronic Publication: 2023 Apr 28.
DOI:	10.1177/10781552231171827
Abstrakt:	Objectives: Therapeutic drug monitoring aims to quantify the concentration of a drug in a biological matrix. In oncology, the therapeutic arsenal is vast and therapeutic drug monitoring optimizes treatment and reduces costs. This review will analyze the financial impact of therapeutic monitoring of anticancer drugs in healthcare institutions. Methods: Keywords were selected using Decs (MeSH). Through the Pubmed, Scopus, and Virtual Health Library (VHL) databases, 74 articles were found, of which 4 meet the inclusion criteria. Methodological quality and risk of bias were assessed according to the Research Triangle Institute Item Bank (RTI-Item Bank) scale. Key Findings: Therapeutic drug monitoring is an important tool for dose reduction or dose increase due to toxicity and lack of response, respectively. The main barriers are associated costs and lack of cost-benefit data. An alternative is to use population pharmacokinetic models, measured plasma concentration(s) and relevant patient characteristics, estimated individual pharmacokinetic parameters, and predicted drug concentrations at any point in the dosing range. Conclusions: Therapeutic drug monitoring is understood as a technology that adds costs to payers. Future studies should generate clinical evidence of population pharmacokinetics from therapeutic drug monitoring studies.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu